Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE

Farghaly, Mohamed; Dallal, Sara Ahmad Mohammad Al; Fasseeh, A.N.; Monsef, Nahed; Suliman, Eldaw; Tahoun, Mohamed Attia; Abaza, Sherif; Kaló, Zoltán

doi:10.3389/fphar.2021.680737

Cited by 12 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Often, orphan-drug technologies are assessed from the perspective of patient, public, or government preferences (Badia et al, 2019;van Overbeeke et al, 2019;Kwon et al, 2017;Laba et al, 2020;Kolasa et al, 2018). There are also several studies focusing on the review in the assessment of rare disease therapies or orphan drugs from the literature's perspective (Baran-Kooiker et al, 2018;Zelei et al, 2021) or a more practical perspective, such as the evaluation and review of case studies (Blonda et al, 2021;Baran-Kooiker et al, 2019;Farghaly et al, 2021).…”

Section: Discussion Of the Resultsmentioning

confidence: 99%

Methods of Multi-Criteria Analysis in Technology Selection and Technology Assessment: A Systematic Literature Review

Kozłowska

2022

Engineering Management in Production and Services

View full text Add to dashboard Cite

Technology assessment and selection problems have gained importance in recent decades as the used technology often determines the enterprises’ competitive advantage. Due to the extensive catalogue of criteria that should be considered and, on the other hand, the extensive catalogue of available technologies and solutions, the decision-making process of choosing a technology becomes a significant challenge for organisations and individuals. This study aims to identify the main research directions and trends in the scientific literature on applying multi-criteria analysis (MCA) in the context of technology assessment and/or technology selection. The author conducted a bibliometric analysis of publications indexed in the Web of Science and Scopus databases. The methodology of this study also included identifying the most productive authors, countries, organisations, and journals and analysing the occurrence and co-occurrence of terms. Final analyses included 380 publications retrieved from the Scopus database and 311 documents retrieved from the Web of Science repository. The analysis of the occurrence of terms and keywords allowed distinguishing two main research directions in using MCA methods in assessing and selecting industrial and health and medicine-related technologies. Some sub-areas have also been distinguished within these two areas: energy and renewable energy technologies, waste management, biomedical and medical technologies, and drug production technologies.

show abstract

Section: Discussion Of the Resultsmentioning

confidence: 99%

Methods of Multi-Criteria Analysis in Technology Selection and Technology Assessment: A Systematic Literature Review

Kozłowska

2022

Engineering Management in Production and Services

View full text Add to dashboard Cite

show abstract

“…Either way, an evidence-based systematic approach for decision-making is required. Recently, MCDA is gaining momentum across several jurisdictions for assessing the value of off-patent drugs and to support public policy decisions [8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt

Elezbawy¹,

Fasseeh

Sedrak

et al. 2022

J of Pharm Policy and Pract

Self Cite

View full text Add to dashboard Cite

Background Multi- criteria decision analysis (MCDA) can assist policymakers in objectively choosing between alternative therapeutic options based on multiple value attributes. Our aim was to create an MCDA tool for the national tenders of off-patent oncology medicines in Egypt. Methods An initial list of criteria was developed through a literature review complemented by local expert interviews. Price or cost-related criteria were excluded to abide by the national regulations of the tender process. Next, a workshop hosting diversified stakeholders representing different governmental bodies was held. Anonymous voting was used to rank and weigh the criteria as well as assigning scores. Price was added as a separate step to identify best option based on price per point. The tool was then tested on a national tender sample of off-patent oncology medicines to assess its performance, and it was readjusted accordingly in a second workshop. Results Seven non-price criteria were selected, including use in reference countries (23.49% weight), equivalence with the reference product (18.79%), manufacturing quality (15.53%), provision of pharmacovigilance services (12.94%), supply reliability (10.78%), previous use in local settings (9.8%) and macroeconomic benefit (8.67%). A medicine receives a score ranging from 0 to 100% of each criterion’s weight. The aggregated score is calculated on a hundred-point scale. Based on participants’ consensus, an overall score of 65 was set as a cut-off for passing the technical eligibility phase of the tendering process. Any product receiving a lower score would be disqualified from the tender. For qualified products, the lower price per point represents preferential option for the national tender. Conclusions The created MCDA tool is capable of objectively comparing similar off-patent oncology medicines by considering multiple value attributes and providing reliable scoring functions for each.

show abstract

“…In MENA countries, few pilot studies used the MCDA model in the region for healthcare applications, to create a value-based system to assess innovative/biology drugs in Egypt (5) or to purchase generic medicines, in Kuwait (6), and in the UAE (7). A broader utilization of the MCDA model in the region is considered to increase the consistency and transparency of policy decisions (8).…”

Section: Introductionmentioning

confidence: 99%

Multi-Criteria Decision Analysis to Prioritize People for COVID-19 Vaccination When Vaccines Are in Short Supply

Masmoudi¹,

Rhili²,

Zamali³

et al. 2022

Front.Health Serv.

View full text Add to dashboard Cite

COVID-19 pandemic underscored the need for a rapid tool supporting decision-makers in prioritizing patients in the immediate and overwhelming context of pandemics, where shortages in different healthcare resources are faced. We have proposed Multi-Criteria Decision Analysis (MCDA) to create a system of criteria and weights to prioritize uses of COVID-19 vaccines in groups of people at significantly higher risk of severe COVID-19 disease or death, when vaccines are in short supply, for use in Tunisia. The prioritization criteria and the levels within each criterion were identified based on available COVID-19 evidence with a focus on the criteria selected by Tunisian scientific committees. To determine the weights for the criteria and levels, reflecting their relative importance, a panel of frontline physicians treating COVID-19 were invited to participate in an online survey using 1,000 minds MCDA software (www.1000minds.com) which implements the PAPRIKA (Potentially All Pairwise RanKings of all possible Alternatives) method. Ten criteria and twenty-three levels have been selected for prioritizing the uses of COVID-19 vaccines in groups of people at significantly higher risk of severe disease or death. Among the invited physicians, sixty have completed the survey. The obtained scores were, in decreasing order of importance (mean weights in parentheses, summing to 100%). Obesity (16.2%), Age (12.7%), Chronic pulmonary diseases (10.8%), Chronic cardiovascular conditions (10.3%), Bone marrow or organ transplantation (10.1%), Immunodeficiency or Immunosuppression (9.6%), Diabetes (9%), Renal failure (8.4%), evolutive cancer (6.9%), and high blood pressure (6%). MCDA-based prioritization scoring system comprising explicit criteria and weights provides an adaptable and multicriteria approach that can assist policy-makers to prioritize uses of COVID-19 vaccines.

show abstract

Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE

Cited by 12 publications

References 24 publications

Methods of Multi-Criteria Analysis in Technology Selection and Technology Assessment: A Systematic Literature Review

Methods of Multi-Criteria Analysis in Technology Selection and Technology Assessment: A Systematic Literature Review

A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt

Multi-Criteria Decision Analysis to Prioritize People for COVID-19 Vaccination When Vaccines Are in Short Supply

Contact Info

Product

Resources

About